Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
|ClinicalTrials.gov Identifier: NCT01706185|
Recruitment Status : Completed
First Posted : October 15, 2012
Last Update Posted : October 22, 2012
|Condition or disease||Intervention/treatment|
|Pathologically Demonstrated Bladder Cancer||Other: Data acquisition and analysis|
There will be no procedure(s) or treatment(s) carried out on patients. All data and samples will be taken from those already stored at the investigation sites. Clinical data collected will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system) [TNM stage], and histopathologic description only. Strict anonymity of patient data will be maintained.
This retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.
|Study Type :||Observational|
|Actual Enrollment :||156 participants|
|Official Title:||Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||January 2008|
Other: Data acquisition and analysis
Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
- To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer. [ Time Frame: Up to 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706185
|GSK Investigational Site|
|Leuven, Belgium, 3000|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|